Arcturus Therapeutics (NASDAQ:ARCT) Issues Quarterly Earnings Results

Arcturus Therapeutics (NASDAQ:ARCT) posted its quarterly earnings data on Thursday. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78), Zacks reports. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%.

Arcturus Therapeutics Stock Performance

ARCT traded down $0.08 on Thursday, reaching $15.97. The company had a trading volume of 297,811 shares, compared to its average volume of 412,739. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00. The stock has a market cap of $432.58 million, a P/E ratio of -7.19 and a beta of 2.62. The company’s fifty day moving average is $17.02 and its 200 day moving average is $18.66.

Wall Street Analysts Forecast Growth

ARCT has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research report on Friday, February 14th. BTIG Research began coverage on Arcturus Therapeutics in a report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, December 16th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $65.00.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.